Cargando…

Automated Drug Coding Using Artificial Intelligence: An Evaluation of WHODrug Koda on Adverse Event Reports

INTRODUCTION: Coding medicinal products described on adverse event (AE) reports to specific entries in standardised drug dictionaries, such as WHODrug Global, is a time-consuming step in case processing activities despite its potential for automation. Many organisations are already partially automat...

Descripción completa

Detalles Bibliográficos
Autores principales: Meldau, Eva-Lisa, Bista, Shachi, Rofors, Emma, Gattepaille, Lucie M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114093/
https://www.ncbi.nlm.nih.gov/pubmed/35579817
http://dx.doi.org/10.1007/s40264-022-01162-7
_version_ 1784709708484968448
author Meldau, Eva-Lisa
Bista, Shachi
Rofors, Emma
Gattepaille, Lucie M.
author_facet Meldau, Eva-Lisa
Bista, Shachi
Rofors, Emma
Gattepaille, Lucie M.
author_sort Meldau, Eva-Lisa
collection PubMed
description INTRODUCTION: Coding medicinal products described on adverse event (AE) reports to specific entries in standardised drug dictionaries, such as WHODrug Global, is a time-consuming step in case processing activities despite its potential for automation. Many organisations are already partially automating drug coding using text-processing methods and synonym lists, however addressing challenges such as misspellings, abbreviations or ambiguous trade names requires more advanced methods. WHODrug Koda is a drug coding engine using text-processing algorithms, built-in coding rules and machine learning to code drug verbatims to WHODrug Global. OBJECTIVE: Our aim was to evaluate the drug coding performance of WHODrug Koda on AE reports from VigiBase, the World Health Organization’s global database of individual case safety reports, in terms of level of automation and coding quality. METHODS: Koda was evaluated on 4.8 million drug entries from VigiBase. Automation level was computed as the proportion of drug entries automatically coded by Koda and was compared to a simple case-insensitive text-matching algorithm. Coding quality was evaluated in terms of coding accuracy, by comparing Koda’s prediction to the WHODrug entries found on the AE reports in VigiBase. To better understand the cases in which Koda’s coding results did not match with the WHODrug entries in VigiBase, a manual assessment of 600 samples of disagreeing encodings was performed by two teams of expert drug coders. RESULTS: Compared with a simple direct-match baseline, Koda can increase the automation level from 61% to 89%, while providing high coding quality with an accuracy of 97%. CONCLUSIONS: Even though Koda was designed for use in clinical trials, Koda achieves automation level and coding quality for drug coding of AE reports comparable with the performance observed in a previous evaluation of Koda on clinical trial data. Koda can thus help organisations to automate their drug coding of AE reports to a large degree.
format Online
Article
Text
id pubmed-9114093
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-91140932022-05-19 Automated Drug Coding Using Artificial Intelligence: An Evaluation of WHODrug Koda on Adverse Event Reports Meldau, Eva-Lisa Bista, Shachi Rofors, Emma Gattepaille, Lucie M. Drug Saf Original Research Article INTRODUCTION: Coding medicinal products described on adverse event (AE) reports to specific entries in standardised drug dictionaries, such as WHODrug Global, is a time-consuming step in case processing activities despite its potential for automation. Many organisations are already partially automating drug coding using text-processing methods and synonym lists, however addressing challenges such as misspellings, abbreviations or ambiguous trade names requires more advanced methods. WHODrug Koda is a drug coding engine using text-processing algorithms, built-in coding rules and machine learning to code drug verbatims to WHODrug Global. OBJECTIVE: Our aim was to evaluate the drug coding performance of WHODrug Koda on AE reports from VigiBase, the World Health Organization’s global database of individual case safety reports, in terms of level of automation and coding quality. METHODS: Koda was evaluated on 4.8 million drug entries from VigiBase. Automation level was computed as the proportion of drug entries automatically coded by Koda and was compared to a simple case-insensitive text-matching algorithm. Coding quality was evaluated in terms of coding accuracy, by comparing Koda’s prediction to the WHODrug entries found on the AE reports in VigiBase. To better understand the cases in which Koda’s coding results did not match with the WHODrug entries in VigiBase, a manual assessment of 600 samples of disagreeing encodings was performed by two teams of expert drug coders. RESULTS: Compared with a simple direct-match baseline, Koda can increase the automation level from 61% to 89%, while providing high coding quality with an accuracy of 97%. CONCLUSIONS: Even though Koda was designed for use in clinical trials, Koda achieves automation level and coding quality for drug coding of AE reports comparable with the performance observed in a previous evaluation of Koda on clinical trial data. Koda can thus help organisations to automate their drug coding of AE reports to a large degree. Springer International Publishing 2022-05-17 2022 /pmc/articles/PMC9114093/ /pubmed/35579817 http://dx.doi.org/10.1007/s40264-022-01162-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research Article
Meldau, Eva-Lisa
Bista, Shachi
Rofors, Emma
Gattepaille, Lucie M.
Automated Drug Coding Using Artificial Intelligence: An Evaluation of WHODrug Koda on Adverse Event Reports
title Automated Drug Coding Using Artificial Intelligence: An Evaluation of WHODrug Koda on Adverse Event Reports
title_full Automated Drug Coding Using Artificial Intelligence: An Evaluation of WHODrug Koda on Adverse Event Reports
title_fullStr Automated Drug Coding Using Artificial Intelligence: An Evaluation of WHODrug Koda on Adverse Event Reports
title_full_unstemmed Automated Drug Coding Using Artificial Intelligence: An Evaluation of WHODrug Koda on Adverse Event Reports
title_short Automated Drug Coding Using Artificial Intelligence: An Evaluation of WHODrug Koda on Adverse Event Reports
title_sort automated drug coding using artificial intelligence: an evaluation of whodrug koda on adverse event reports
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114093/
https://www.ncbi.nlm.nih.gov/pubmed/35579817
http://dx.doi.org/10.1007/s40264-022-01162-7
work_keys_str_mv AT meldauevalisa automateddrugcodingusingartificialintelligenceanevaluationofwhodrugkodaonadverseeventreports
AT bistashachi automateddrugcodingusingartificialintelligenceanevaluationofwhodrugkodaonadverseeventreports
AT roforsemma automateddrugcodingusingartificialintelligenceanevaluationofwhodrugkodaonadverseeventreports
AT gattepailleluciem automateddrugcodingusingartificialintelligenceanevaluationofwhodrugkodaonadverseeventreports